Pharmacological testing in the diagnosis of arrhythmias

Minerva Cardioangiologica

Volumn 58, Issue 4, 2010, Pages 505-517

  Brembilla Perrot, B ^a  

^a CHU NANCY BRABOIS   (France)

Author keywords

Bradycardia; Diagnosis; Pharmacology; Tachycardia

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; AJMALINE; ATROPINE; FLECAINIDE; GLYCERYL TRINITRATE; ISOPRENALINE; PROPRANOLOL;

ARRHYTHMOGENESIS; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRUGADA SYNDROME; CARDIOMYOPATHY; DIAGNOSTIC VALUE; EXERCISE; FAMILY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART PREEXCITATION; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE TACHYCARDIA; HUMAN; INJECTION; PROGNOSIS; REENTRY ARRHYTHMIA; REFRACTORY PERIOD; REVIEW; SICK SINUS SYNDROME; SUDDEN DEATH; SYNCOPE;

ARRHYTHMIAS, CARDIAC; BRADYCARDIA; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK; TACHYCARDIA;

EID: 78751608590     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Flammang D, Church T, Waynberger M, Chassing A, Antiel M. Can Adenosine 5′-triphosphate be used to select treatment in severe vasovagal syndrome? Circulation 1997;96:1201-8.
2. Donateo P, Brignole M, Menozzi C, Bottoni N, Alboni P, Dinelli M et al. Mechanism of syncope in patients with positive adenosine triphosphate tests. J Am Coll Cardiol 2003;41:93-8.
3. Flammang D, Erickson M, McCarville S, Church T, Hamani D, Donal E. Contribution of head-up tilt testing and ATP testing in assessing the mechanisms of vasovagal syndrome: preliminary results and potential therapeutic implications. Circulation 1999;99:2427-33.
4. Burnett D, Abi-Samra F, Vacek JL. Use of intravenous adenosine as a noninvasive diagnostic test for sick sinus syndrome. Am Heart J 1999;137:435-8.
5. Fragakis N, Iliadis I, Sidopoulos E, Lambrou A, Tsaritsaniotis E, Katsaris G. The value of adenosine test in the diagnosis of sick sinus syndrome: susceptibility of sinus and atrioventricular node to adenosine in patients with sick sinus syndrome and unexplained syncope. Europace 2007;9:559-62.
6. Parry SW, Nath S, Bourke JP, Bexton RS, Kenny RA. Adenosine test in the diagnosis of unexplained syncope: marker of conducting tissue disease or neurally mediated syncope? Eur Heart J 2006;27:1396-400.
7. Waxman MB, Yao L, Cameron DA, Wald RW, Roseman J. Isoproterenol induction of vasodepressor-type reaction in vasodepressor-prone persons. Am J Cardiol 1989;63:58-65.
8. Sheldon R, Killam S. Methodology of isoproterenol tilt-table testing in patients with syncope. J Am Coll Cardiol 1992;19:773-9.
9. Vlay SC, Brodsky C, Vlay LC. Safety and tolerability of an aggressive tilt table test protocol in the evaluation of patients with suspected neurocardiogenic syncope. PACE 2000;23:441-5.
10. Sheldon R. Effects of aging on responses to isoproterenol tilt-table testing in patients with syncope. Am J Cardiol 1994;74:459-63.
11. Moya A, Sutton R, Ammirati F, Blanc JJ, Brignole M, Dahm JB et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS); European Society of Emergency Medicine (EuSEM); European Federation of Internal Medicine (EFIM); European Union Geriatric Medicine Society (EUGMS); American Geriatrics Society (AGS); European Neurological Society (ENS); European Federation of Autonomic Societies (EFAS); American Autonomic Society (AAS). Eur Heart J 2009;30:2631-71.
12. Tonet JL, Frank R, Fontaine G, Lajeuncomme MR, Vedel J, Petitot JC et al. Evaluation of the response to the ajmaline test in the diagnosis of paroxysmal atrioventricular blocks. Arch Mal Coeur Vaiss 1983;76:1154-62.
13. Moya A, Brignole M, Menozzi C, Garcia-Civera R, Tognarini S, Mont L et al. Mechanism of syncope in patients with isolated syncope and in patients with tilt-positive syncope. Circulation 2001;104:1261-7.
14. Perrot B, Houppe JP, Faivre G. Critical study of technics for studying sinus function and search for a definition of criteria for electrophysiological study of sinus function. Ann Cardiol Angeiol 1982;31:425-34.
15. Brembilla-Perrot B, Terrier de la Chaise A. Provocation of supraventricular tachycardias by an intravenous class I antiarrhythmic drug. Int J Cardiol 1992;34:189-98.
16. Brembilla-Perrot B, Muhanna I, Nippert M, Popovic B, Beurrier D, Houriez P et al. Paradoxical effect of isoprenaline infusion. Europace 2005;7:621-7.
17. Schweitzer P, Mark H. The effect of atropine on cardiac arrhythmias and conduction. Part 1. Am Heart J 1980;100:119-27.
18. Schweitzer P, Mark H. The effect of atropine on cardiac arrhythmias and conduction. Part 2. Am Heart J 1980;100:255-61.
19. Vavetsi S, Nikolaou N, Tsarouhas K, Lymperopoulos G, Kouzanidis I, Kafantaris I et al. Consecutive administration of atropine and isoproterenol for the evaluation of asymptomatic sinus bradycardia. Europace 2008;10:1176-81.
20. Jordan JL, Yamaguchi I, Mandel WJ. Studies on the mechanism of sinus node dysfunction in the sick sinus syndrome. Circulation 1978; 57: 217-23.
21. Mangiardi LM, Bonamini R, Conte M, Gaita F, Orzan F, Presbitero P et al. Bedside evaluation of atrioventricular block with narrow QRS complexes: usefulness of carotid sinus massage and atropine administration. Am J Cardiol 1982;49:1136-45.
22. Markel ML, Miles WM, Zipes DP, Prystowsky EN. Parasympathetic and sympathetic alterations of Mobitz type II heart block. J Am Coll Cardiol 1988;11:271-5.
23. Matina D, Faugère G, Lévy S, Gérard R. Exercise test in isolated anomalies of auriculo-ventricular conduction in children and adolescents. Value in idiopathic auriculo-ventricular blocks and ventricular pre-excitation syndromes. Arch Mal Coeur Vaiss 1984;77:550-6.
24. Vargas G, Akhtar M, Damato AN. Electrophysiologic effects of isoproterenol on cardiac conduction system in man. Am Heart J 1975;90:25-34.
25. Brembilla-Perrot B, Terrier De La Chaise A, Pichené M, Aliot E, Cherrier F, Pernot C. Isoprenaline as an aid to the induction of catecholamine dependent supraventricular tachycardias during programmed stimulation. Br Heart J 1989;61:348-55.
26. Hatzinikolaou H, Rodriguez LM, Smeets JLRM, Timmermans T, Vrouchos G, Grecas G et al. Isoprenaline and inducibility of atrioventricular nodal re-entrant tachycardia. Heart 1998;79:165-8.
27. Nguyen N X, Yang PT, Huycke EC, Keung EC, Deedwania P, Sung RJ. Effects of beta-adrenergic stimulation on atrial latency and atrial vulnerability in patients with paroxysmal supraventricular tachycardia. Am J Cardiol 1988; 61: 1031-6
28. Oral H, Crawford T, Frederick M, Gadeela N, Wimmer A, Dey S et al. Inducibility of paroxysmal atrial fibrillation by isoproterenol and its relation to the mode of onset of atrial fibrillation. J Cardiovasc Electrophysiol 2008;19:466-70.
29. Freedman RA, Swerdlow CD, Echt DS, Winkle RA, Doderholm-Difatte V, Mason JW. Facilitation of ventricular tachyarrhythmia induction by isoproterenol. Am J Cardiol 1984;54:765-70.
30. Reddy CP, Gettes LS. Use of isoproterenol as an aid to electric induction of chronic recurrent ventricular tachycardia. Am J Cardiol 1979;44:705-13.
31. Niebauer M, Daoud E, Goyal R, Chan KK, Harvey M, Bogun F et al. Use of isoproterenol during programmed ventricular stimulation in patients with coronary artery disease and nonsustained ventricular tachycardia. Am Heart J 1996 ; 132 : 516-8
32. Brembilla-Perrot B, Donetti J, Terrier De La Chaise A, Sadoul N, Aliot E, Juillière Y. Diagnosis value of ventricular stimulation in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 1991;121:1124-31.
33. Calkins H, Marcus F. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: an update. Curr Cardiol Rep 2008;10:367-75.
34. Olshansky B, Martins JB. Usefulness of isoproterenol facilitation of ventricular tachycardia induction during extrastimulus testing in predicting effective chronic therapy with beta-adrenergic blockade. Am J Cardiol 1987;59:573-7.
35. Haissaguerre M, Montserrat P, Le Metayer P, Barrat JL, Warin JF. Intérêts du test à l'isoprénaline dans les cardiopathies arythmogènes. Arch Mal Cœur 1989;82:1845-53.
36. Brembilla-Perrot B, Admant P, Le Helloco A, Pernot C. Loss of efficacy of flecainide in the Wolff-Parkinson-White syndrome after isoproterenol administration. Eur Heart J 1985;6:1074-8.
37. Manolis AS, Estes NA 3rd. Reversal of electrophysiologic effects of flecainide on the accessory pathway by isoproterenol in the Wolff-Parkinson- White syndrome. Am J Cardiol 1989;64:194-8.
38. Jazayeri MR, Van Wyhe G, Avitall B, McKinnie J, Tchou P, Akhtar M. Isoproterenol reversal of antiarrhythmic effects in patients with inducible sustained ventricular tachyarrhythmias. J Am Coll Cardiol 1989;14:705-11.
39. Crawford T, Chugh A, Good E, Yoshida K, Jongnarangsin K, Ebinger M et al. Clinical Value of Noninducibility by High-Dose Isoproterenol Versus Rapid Atrial Pacing After Catheter Ablation of Paroxysmal Atrial Fibrillation. J Cardiovasc Electrophysiol 2010;21:13-20.
40. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation 2002;105:2753-9.
41. Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol 1996;7:999-1007.
42. Yamawake N, Nishizaki M, Hayashi T, Niki S, Maeda S, Tanaka Y et al. Autonomic and pharmacological responses of idiopathic ventricular tachycardia arising from the left ventricular outflow tract. J Cardiovasc Electrophysiol 2007;18:1161-6.
43. Horie T, Miyauchi Y, Kobayashi Y, Iwasaki YK, Maruyama M, Katoh T, Takano T. Adenosine-sensitive atrial tachycardia originating from the proximal coronary sinus. Heart Rhythm 2005;2:1301-8.
44. Glatter KA, Cheng J, Dorostkar P, Modin G, Talwar S, Al-Nimri M et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation 1999;99:1034-40.
45. Rinne C, Sharma AD, Klein GJ, Yee R, Szabo T. Comparative effects of adenosine triphosphate on accessory pathway and atrioventricular nodal conduction. Am Heart J 1988;115:1042-7.
46. Keim S, Werner P, Jazayeri M, Akhtar M, Tchou P. Localization of the fast and slow pathways in atrioventricular nodal reentrant tachycardia by intraoperative ice mapping. Circulation 1992;86:919-25.
47. Belhassen B. Utilisation diagnostique de l'adénosine triphosphate dans les arythmies cardiaques. Arch Mal Cœur 2002;95:57-63.
48. Garratt CJ, Antoniou A, Griffith MJ, Ward DE, Camm AJ. Use of intravenous adenosine in sinus rhythm as a diagnostic test for latent preexcitation. Am J Cardiol 1990;65:868-73.
49. Ninomiya Y, Iriki Y, Ishida S, Oketani N, Matsushita T, Ichiki H et al. Usefulness of the adenosine triphosphate with a sufficient observation period for detecting reconduction after pulmonary vein isolation. Pacing Clin Electrophysiol 2009;32:1307-12.
50. Wellens HJ, Brugada P, Roy D, Weiss J, Bär FW. Effect of isoproterenol on the anterograde refractory period of the accessory pathway in patients with the Wolff-Parkinson-White syndrome. Am J Cardiol 1982;50:180-4.
51. Brembilla-Perrot B, Terrier de la Chaise A, Marçon F, Cherrier F, Pernot C Should the Isuprel test be performed systematically in Wolff-Parkinson-White syndrome? Arch Mal Coeur Vaiss 1988;81:1227-33.
52. Perrot B, Clozel JP, Faivre G. Effect of adenosine triphosphate on the accessory pathways. Eur Heart J 1984;5:382-93.
53. Wellens HJ, Bär FW, Dassen WR, Brugada P, Vanagt EJ, Farré J. Effect of drugs in the Wolff-Parkinson-White syndrome. Importance of initial length of effective refractory period of the accessory pathway. Am J Cardiol 1980;46:665-9.
54. Fananapazir L, Packer DL, German LD, Greer GS, Gallagher JJ, Pressley JC et al. Procainamide infusion test: inability to identify patients with Wolff-Parkinson-White syndrome who are potentially at risk of sudden death. Circulation 1988;77:1291-6.
55. Veltmann C, Wolpert C, Sacher F, Mabo P, Schimpf R, Streitner F et al. Response to intravenous ajmaline: a retrospective analysis of 677 ajmaline challenges. Europace 2009;11:1345-52.
56. Brugada R, Brugada P, Brugada J. Electrocardiogram interpretation and class I blocker challenge in Brugada syndrome. J Electrocardiol 2006;39:115-8.
57. Rolf S, Bruns HJ, Wichter T, Kirchhof P, Ribbing M, Wasmer K et al. The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur Heart J 2003;24:1104-12.
58. Gasparini M, Priori SG, Mantica M, Napolitano C, Galimberti P, Ceriotti C et al. Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol 2003;26:338-41.
59. Wolpert C, Echternach C, Veltmann C, Antzelevitch C, Thomas GP, Spehl S et al. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2005;2:254-60.